Table 1 Patients’ demographic and baseline clinical characteristics (n = 89)
Characteristic | Count (%) |
|---|---|
Gender, n (%) | |
  Male | 45 (49) |
  Female | 44 (51) |
Age, n (%) | |
  < 60 years | 57 (64) |
  ≥ 60 years | 32 (36) |
Race, n (%) | |
  Non-Hispanic White | 63 (71) |
  African-American | 18 (20) |
  Hispanic | 8 (9) |
Performance status, n (%) | |
  0 | 35 (39) |
  1 | 49 (55) |
  2 | 5 (6) |
Histological grade | |
  Well | 3 (3) |
  Moderate | 69 (78) |
  Poor | 17 (19) |
Number of metastatic sites | |
< 3 | 42 (47) |
≥ 3 | 47 (53) |
Serum albumin | |
  Normal | 72 (81) |
  Low (<3.5 g/dL) | 17 (19) |
Serum LDH | |
  Normal | 19 (21) |
  Elevated (>618 IU/L) | 70 (79) |
RMH Score | |
  < 2 | 43 (48) |
  ≥ 2 | 46 (52) |
KRAS exon 2 wild-typea | 89 (100) |
  KRAS non-exon 2 mutations (n = 70) | 0 |
  NRAS mutations (n = 23) | 0 |
  BRAF V600E mutation (n = 64) | 0 |
  PIK3CA mutations (n = 37) | 6 |